PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-173585 | Service
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET
7.1 GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Catalent
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Lonza
16.3 Patheon
16.4 Fareva
16.5 Aenova
16.6 Boehringer Ingelheim
16.7 Siegfried
16.8 Recipharm AB
16.9 AMRI
16.10 Eurofins CDMO
16.11 WuXi AppTec Group
16.12 FAMAR Health Care Services
16.13 Piramal Pharma Solutions
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeActive Pharmaceutical Ingredient (API) Manufacturing
Finished Dosage Formulation (FDF) Development & Manufacturing
Secondary Packaging
By Application
Pre-clinical
Phase I
Phase II
Phase III
Phase IV
Companies
Catalent
Lonza
Patheon
Fareva
Aenova
Boehringer Ingelheim
Siegfried
Recipharm AB
AMRI
Eurofins CDMO
WuXi AppTec Group
FAMAR Health Care Services
Piramal Pharma Solutions
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.